根据Clarivate的2025年报告,尽管资金少,但七家新开办企业仍在推动创新型妇女保健治疗。 Seven startups are advancing innovative women’s health treatments despite low funding, according to Clarivate’s 2025 report.

Cleivate的2025年观察公司报告突显了七家全球创业企业通过开发新颖的治疗方法,如内分泌硬化、PCOS和产后抑郁症等,解决长期存在的妇女健康差距问题。 Clarivate’s 2025 Companies to Watch report highlights seven global startups tackling longstanding gaps in women’s health by developing innovative treatments for conditions like endometriosis, PCOS, and postpartum depression. 尽管这些公司只得到15%的风险资本和5%的保健研发资金,但它们正在推进非临床疗法、生育药物、微生物免疫疗法和由精神刺激的心理健康治疗。 Despite receiving only 15% of venture capital and 5% of healthcare R&D funding, these companies are advancing non-hormonal therapies, fertility drugs, microbial immunotherapies, and psychedelic-inspired mental health treatments. 这些公司是根据临床试验、专利和融资选择的,它们代表着向包容、科学驱动的护理的日益转变。 Selected based on clinical trials, patents, and financing, the firms represent a growing shift toward inclusive, science-driven care. 报告强调了研究、监管和投资方面日益增强的势头,表明在解决长期资金不足问题和改善全世界妇女保健成果方面取得进展。 The report underscores increasing momentum in research, regulation, and investment, signaling progress in addressing chronic underfunding and improving health outcomes for women worldwide.